pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·1h ago·1 min read
save

Democratic doctors celebrate gains as MAHA’s future remains uncertain after election

Nov 5, 2026·read at STAT ↗Neutral

The STAT+ D.C. Diagnosis newsletter reports that doctors aligned with the Democratic Party secured notable wins in recent political battles.

At the same time, the Medicare for All (MAHA) initiative faces an uncertain outlook, with its future hinging on upcoming election results and policy debates.

The piece highlights how the election could influence broader health‑care reforms, including Medicare for All, and underscores the political stakes for the health‑care sector.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Winners, losers, and MAHA”

read at STAT ↗
371 words · retrieved 16m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 1h agoSTAT+: Pharmalittle: We’re reading about India’s new manufacturing rules, clinical trials in China, and moreSTAT
  • 2h agoSTAT+: Beyond statins, one drug lowered heart attack risk by 20%STAT
  • 3h agoSTAT+: Medicare delays controversial RPM rule updateSTAT
  • 3h agoSingle-payer health care system proponents were thrown a big bone this electionSTAT
  • 4h agoSTAT+: Revolution Medicines’ pancreatic cancer drug has stunning commercial debutSTAT